Podcasts about laboratory medicine

John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test detects antihypertensive medications in urine, providing evidence of whether patients are absorbing their medications or whether a new treatment approach might be needed. Speaker 3: (00:33) Could you tell us a little about yourselves and your backgrounds? Speaker 3: (01:41) Dr. Taler, could you provide us with a brief background on resistant hypertension? Speaker 3: (03:43) Can you provide a little bit more background on patients who aren't taking their medications? Speaker 3: (05:11) How do physicians currently assess whether patients are taking their medications? Speaker 3: (07:03) Dr. Lieske, could you tell us how this new assay can be used to help physicians manage their patients with hypertension? Speaker 3: (09:43) Dr. Taler, can you tell us how doctors can use this new testing to manage their patients?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Div Dubey, M.B.B.S., a neurologist and co-director of the Clinical Neuroimmunology Laboratory at Mayo Clinic, explore the topic of peripheral neuropathy. Their discussion covers:The high prevalence of peripheral neuropathy and why early diagnosis is important. The complexities involved in diagnosing the condition.Symptoms that should prompt clinicians to order advanced testing early in the diagnostic process.How algorithms are enhancing the use of testing to complement other diagnostic tools.Ongoing discovery related to specific antibodies associated with neuropathies.Learn more in our e-book, "Peripheral neuropathy: Cutting through diagnostic dissonance with an algorithmic approach."

Joseph Yao, M.D., explains how Mayo Clinic Laboratories' new quantitative assay (Mayo ID: ADVQU) goes beyond qualitative testing to evaluate transplant patients for adenovirus infection. Adenovirus can cause life-threatening disease in immunocompromised transplant patients, especially children.(01:14)Could you give us a brief overview of this assay? (02:06)Can you explain the differences of the qualitative and quantitative methods and why we made the change to a quantitative adenovirus method? (04:00)When is this test typically ordered for transplant patients? Is it used throughout their treatment? (06:56)Could an immunocompromised person be unknowingly infected? (07:31)Is our quantitative method approved for pediatric patients? (08:00)How are the test results used to treat patients?(10:36)What other infections might providers consider alongside adeovirus?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss global trends in diagnostic manufacturing and their implications for laboratory professionals. Topics include: Emerging innovations in mass spectrometry, next-generation sequencing, automation, and artificial intelligence. Fierce competition in the global manufacturing landscape as new companies enter the market. Geopolitical dynamics influencing where innovations are deployed. Why laboratory professionals need to drive innovation implementation to maximize benefits for clinicians and their patients.

Send us a textWhy are so many pathologists still afraid of going digital? In this USCAP special episode sponsored by Muse Microscopy, I talk with Dr. Sarah Dry, Chair of Pathology and Laboratory Medicine at UCLA, about real-world adoption, AI fear, and how change is best managed when it's people-led.From her early digital research lab in 2007 to pioneering innovative workflows at UCLA today, Dr. Dry knows how direct-to-digital imaging and AI can enhance, not replace, our work.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the value laboratories deliver for their entire health system. They cover how laboratories impact:Growth in revenueGrowth in lab chargesGrowth in ancillary servicesHospital length of stayControl over expensesYou can also find more in-depth information on this topic in “Maximizing your health system's financial performance,” a white paper with data-driven ways laboratories support their organizations. 

Today, we're speaking to Professor Martijn Schut, Professor of Translational AI in Laboratory Medicine and Professor Henk CPM van Weert, GP and Emeritus Professor of General Practice, both based at Amsterdam University Medical Center.Title of paper: Artificial intelligence for early detection of lung cancer in GPs' clinical notes: a retrospective observational cohort studyAvailable at: https://doi.org/10.3399/BJGP.2023.0489In most cancers, the prognosis depends substantially on the stage at the start of therapy. Therefore, many methods have been developed to enhance earlier diagnosis, for example, logistic regression models, biomarkers, and electronic-nose technology (exhaled volatile organic compounds). However, as most patients are referred by their GP, who keeps life-long histories of enlisted patients, general practice files might contain hidden information that could be used for earlier case finding. An algorithm was developed to identify patients with lung cancer 4 months earlier, just by analysing their files. Contrary to other methods, all medical information available in general practice was used.TranscriptThis transcript was generated using AI and has not been reviewed for accuracy. Please be aware it may contain errors or omissions.Speaker A00:00:01.600 - 00:00:55.370Hello and welcome to BJGP Interviews. I'm Nada Khan and I'm one of the associate editors of the journal. Thanks for taking the time today to listen to this podcast.Today we're speaking to Professor Martin Schutt, who is a professor in translational AI and Laboratory medicine, and Professor Hank Vanwort, GP and Emeritus professor in General Practice, who are both based at Amsterdam University Medical Center. We're here to discuss their paper, which is titled Artificial Intelligence for Early Detection of lung cancer in GP's clinical notes.So, yeah, it's great to see you both here today. And Martin, I'll come to you first.I suppose we know that it's important to try and diagnose cancer early, but could you talk us through what's the potential for artificial intelligence here in terms of identifying cancer earlier based on patient records?Speaker B00:00:55.810 - 00:01:52.220Yeah, that's a very interesting question because the potential kind of like goes hand in hand with the huge amount of interest in AI. And I think there are great opportunities. There are also great challenges.But talking about the opportunities, especially in the context of the article that we wrote, is on the data side. So on the data side, the digitalization of electronic health records gives great opportunities.A lot more is digitalized, and that means that we also, in our case, have access to free text, and that we, with the advent of the large language models, with also new developments in AI, we also have better ways of making use of those data. So those two combined creates a really interesting formula for big opportunities for AI in the general practice and healthcare in general.Speaker A00:01:52.300 - 00:02:05.960And you mentioned access to free text records. So what GPs are typing into the record records?But before we get into the study, can you just briefly describe what is natural language processing and how that can be used in free text records?Speaker B00:02:06.760 - 00:03:10.100So we know that a lot of clinical risk scores, they work with features of patients, so their age and their gender or sex. And. But of course, a lot of information is also written up in unstructured way. And in our case that is...

In this episode of "Lab Medicine Rounds," we explore how to navigate the often-tricky terrain of giving and receiving feedback. Join the conversation as we unpack common pitfalls, reframe defensive reactions, and offer practical tools for fostering growth-minded, judgment-free dialogue. Whether you're leading a team or developing your own feedback skills, this episode offers thoughtful insights you can use right away.  

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss tick-borne diseases. They cover:Different diseases patients can get from ticks. Disease prevention, including Dr. Pritt's A through Z flash cards with tips for people to protect themselves from infectious insects.Laboratory medicine's valuable role in testing and educating providers to diagnose patients quickly and accurately.Clinical areas most likely to encounter patients with tick-borne diseases.Reliable sources for details about the prevalence of different diseases around the country (e.g., U.S. Centers for Disease Control and Prevention (CDC) and Mayo Clinic Laboratories).

On May 8, 2025 we met with Kevin Bieniek to talk about the nature of brain injury seen in chronic traumatic encephalopathy in athletes and others who experience repeated concussion. Kevin explained the commonalities and unique features of those injuries compared to neurodegenerative diseases.Guest:Kevin Bieniek, Associate Professor, Department of Pathology and Laboratory Medicine and Director of the Brain Bank at the Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases at UT Health San Antonio.Participating:Melanie Carless, Department of Neuroscience, Developmental and Regenerative Biology, UTSAHost:Charles Wilson, Department of Neuroscience, Developmental and Regenerative Biology, UTSAThanks to James Tepper for original music

On this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., speaks with Erinn Downs, D.O., professor of laboratory medicine and pathology at Mayo Clinic's Arizona campus, on the topic of benign mimics of malignant breast pathology.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Down Syndrome and Alzheimer's: Clinical Trials, Equity, and Patient-Centered Progress," Elizabeth Head, PhD, professor in the department of Pathology and Laboratory Medicine at the University of California, Irvine, discussed the evolving intersection of Down syndrome and Alzheimer disease using updates from the Alzheimer Biomarker Consortium – Down Syndrome (ABC-DS). She detailed how outcome assessments have been refined to meet the unique cognitive profiles of individuals with Down syndrome and shared the progress in launching clinical trials that now include this historically excluded population. Head also addressed the challenges in distinguishing developmental delay from early dementia symptoms, the potential role of anti-amyloid therapies, and how non-pharmacological interventions like sleep apnea treatment may contribute to cognitive preservation. She emphasized the importance of equitable research participation, clinician education, and understanding patient priorities—like independence and respect—when supporting individuals with Down syndrome and their families. Looking for more Alzheimer disease/dementia discussion? Check out the NeurologyLive® Alzheimer disease/dementia clinical focus page. Episode Breakdown: 1:00 – Overview of the ABC-DS initiative and the growing inclusion of Down syndrome in Alzheimer research 2:00– Current state of clinical trials and progress in therapeutic development for this population 3:30 – Evolution of outcome assessments tailored for individuals with Down syndrome 5:40 – Challenges in distinguishing Down syndrome traits from signs of early dementia 7:40 – Clinician educations needs and improving access to specialized care 9:00 – Neurology News Minute 11:00 – Eligibility and considerations for anti-amyloid therapies in Down syndrome 13:35 – Research gaps, co-occurring conditions, and the importance of reaching underserved populations 16:40 – Top priorities from patients and families: independence, inclusion, and respect in care settings The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: GENERATION HD2 Trial of Huntington Agent Tominersen Amended to Include Only Higher Dose FDA Grants Authorization to Epiminder's Implantable Continuous EEG Monitor for Epilepsy Treatment FDA Approves FcRn Blocker Nipocalimab for Broad Forms of Generalized Myasthenia Gravis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion. They discuss their strategic collaboration and the innovative SAAmplify™–αSYN (CSF) test. They covered: Details about how the cerebrospinal fluid biomarker test (Mayo ID: ASYNC) benefits patients exhibiting signs and symptoms of clinically uncertain cognitive decline or clinically uncertain Parkinsonian syndromes.Groundbreaking science on proteins that Amprion leveraged to create a solution that meaningfully impacts patient care and provides value to clinicians.Information physicians receive from the test, and when they should consider ordering it for their patients. Opportunities to change diagnostic journeys by providing accurate, early diagnosis with SAAmplify–αSYN. 

In this episode of Lab Medicine Rounds, Justin Kreuter, M.D., and Miglena Komforti, D.O., from Mayo Clinic as they discuss threshold diagnoses of the breast — those gray zones that challenge even seasoned professionals. Learn why they're important, how to approach them, and what role technology might play in the future. 

Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.Speaker 3: (00:33) Do you mind telling us a little bit about yourself and your background? Speaker 3: (01:45)Could you please provide us with an overview of arsenic, how people get exposed, and the laboratory testing for arsenic and arsenic speciation? Speaker 3: (05:25)Which patients should have this testing, and when should it be performed? Speaker 3: (06:57)What alternative test options are available, and how does testing at Mayo Clinic compare? Speaker 3: (08:37)How are the results used in patient care?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the recent court judgment on the U.S. Food and Drug Administration's (FDA) oversight of lab-developed tests (LDT). They covered:  Details about the ruling to vacate the FDA's rule on LDT oversight. What LDT oversight might look like in the future. How the laboratory medicine industry can help create an oversight approach that is positive for both patients and innovation. 

Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after organ transplants. Optimal doses can vary by patient ethnicity and are key to successful transplantation.Speaker 3: (00:32) Could you provide us a with little bit about your background and yourself? Speaker 3: (03:45) Will you please provide a brief overview of Mayo test 3A5Q? Speaker 3: (06:56) Which patients should have this testing, and when should it be performed? Speaker 3: (08:15) What alternative or complementary tests should be considered? Speaker 3: (09:25)How are the results used in patient care? Speaker 3: (10:38)Will you help the audience understand the significance of monitoring tacrolimus levels for transplant rejection? Speaker 3: (12:53)What alleles are included in this test?

As we approach Lab Week, this episode of “Lab Medicine Rounds” includes a compilation of interviews from previous episodes highlighting the pivotal role laboratory professionals play in healthcare. Featured interviews include Dr. Eric Hsi, Dr. Curt Hanson, and Jane Hermansen, all from Mayo Clinic in Rochester, Minnesota.Discussion includes:·       The importance of highlighting the laboratory presence in current medical practice.·       How laboratory medicine is informing the future successes of the field.·       Wishes for the future of laboratory medicine and pathology.Timestamps:00:30: Interview w/Dr. Hsi·       Why is it important to highlight the presence of the laboratory in current medical practice?·       What would be your advice for clinicians who haven't thought about the role the laboratory plays, and how to bring it more explicitly into their practice?·       Where is the laboratory headed? ·       What do you think might be the biggest challenge in stepping forward into more of the clinical domain?05:32: Interview w/Dr. Hanson·       Why is it important in lab medicine to look at the past when planning for the future?·       How do you see certain aspects of laboratory medicine informing the future successes of the field?·       How do we as laboratory professionals, shift from being service-oriented to being colleagues/equals with other health care professionals?07:45: Interview w/Jane Hermansen·       What do you wish for the future of laboratory medicine and pathology?

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.During their conversation, Dr. Morice and Dr. Tan explore:Inspiration for developing the liquid biopsy.Features that differentiate LiquidHALLMARK® from existing cancer tests.Patients who will benefit from the test and how an oncologist might use the results.The future potential of liquid biopsy advancements.

Rural America is a vital part of our nation—rich in culture, community, and resilience. But potential Medicaid cuts coupled with the impending expiration of enhanced tax credits further threatens rural communities' access to health care and puts the strength of rural communities at risk. In this episode, Chip Kahn is joined once again by Alan Morgan, CEO of the National Rural Health Association, to explore the impacts of Medicaid cuts and Americans' loss of health coverage on rural hospitals and what is at stake for patient care if lawmakers fail to protect these institutions.Key topics include: The current state of rural health care and why it matters to all Americans;What hospital closures mean for rural patients;The policy levers that could make or break the future of rural hospitals; and,Why Medicaid and the enhanced tax credits are essential to access care.References: Washington Post “Republican Medicaid cuts could shutter rural hospitals, maternity care” (https://www.washingtonpost.com/health/2025/03/08/medicaid-cuts-rural-hospitals/)About: Alan Morgan joined NRHA staff in 2001 and currently serves as Chief Executive Officer of the association.  Recognized as among the top 100 most influential people in health care by Modern Healthcare Magazine, Alan Morgan serves as Chief Executive Officer for the National Rural Health Association. He has more than 30 years experience in health policy at the state and federal level, and is one of the nation's leading experts on rural health policy.Mr. Morgan served as a contributing author for the publications, “Policy & Politics in Nursing and Health Care,” “The Handbook of Rural Aging” and for the publication, “Rural Populations and Health.” In addition, his health policy articles have been published in: The American Journal of Clinical Medicine, The Journal of Rural Health, The Journal of Cardiovascular Management, The Journal of Pacing and Clinical Electrophysiology, Cardiac Electrophysiology Review, and in Laboratory Medicine. Mr. Morgan served as staff for former US Congressman Dick Nichols and former Kansas Governor Mike Hayden. Additionally, his past experience includes tenures as a health care lobbyist for the American Society of Clinical Pathologists, the Heart Rhythm Society, and for VHA Inc.He holds a bachelor's degree in journalism from University of Kansas, and a master's degree in public administration from George Mason University.

Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN Recorded on March 18, 2025 Angela Dispenzieri, MD Consultant, Division of Hematology Serene M. and Frances C. Durling Professor of Medicine and of Laboratory Medicine and Pathology Mayo Clinic Rochester, MN Join us as we dive into in the complex care of amyloid and myeloma with Dr. Angela Dispenzieri from Mayo Clinic Rochester, Minnesota. She explains the diagnosis and explores the differences between amyloid and myeloma. Discussion on treatment strategies for complex cases, side effects of therapies, and difficult conversations with patients, provide practical information on patient care. Tune in today to learn more about the complexities of myeloma. This episode is supported by GSK plc.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the evolution of retail health. They cover several key topics, including:The emergence of retail health locations.Three types of care that are well-suited for a retail approach to healthcare.The importance of incorporating diagnostics when designing retail health.Keep up with the latest diagnostic news and Dr. Morice's insights on LinkedIn and X. 

In this installment of the Longevity & Aging Series, Dr. Julia Sidorova from the Department of Laboratory Medicine and Pathology at the University of Washington (Seattle, WA) joined host Dr. Evgeniy Galimov to discuss her co-authored research paper from Volume 16, Issue 20 of Aging (Aging-US), titled “Werner syndrome RECQ helicase participates in and directs maintenance of the protein complexes of constitutive heterochromatin in proliferating human cells.” DOI - https://doi.org/10.18632/aging.206132 Corresponding Author - Julia M. Sidorova - julias@uw.edu Video interview - https://www.youtube.com/watch?v=3yn8O-JA6GE Abstract Werner syndrome of premature aging is caused by mutations in the WRN RECQ helicase/exonuclease, which functions in DNA replication, repair, transcription, and telomere maintenance. How the loss of WRN accelerates aging is not understood in full. Here we show that WRN is necessary for optimal constitutive heterochromatin levels in proliferating human fibroblasts. Locally, WRN deficiency derepresses SATII pericentromeric satellite repeats but does not reduce replication fork progression on SATII repeats. Globally, WRN loss reduces a subset of protein-protein interactions responsible for the organization of constitutive heterochromatin in the nucleus, namely, the interactions involving Lamin B1 and Lamin B receptor, LBR. Both the mRNA level and subcellular distribution of LBR are affected by WRN deficiency, and unlike the former, the latter phenotype does not require WRN catalytic activities. The phenotypes of heterochromatin disruption seen in WRN-deficient proliferating fibroblasts are also observed in WRN-proficient fibroblasts undergoing replicative or oncogene-induced senescence. WRN interacts with histone deacetylase 2, HDAC2; WRN/HDAC2 association is mediated by heterochromatin protein alpha, HP1α, and WRN complexes with HP1α and HDAC2 are downregulated in senescing cells. The data suggest that the effect of WRN loss on heterochromatin is separable from senescence program, but mimics at least some of the heterochromatin changes associated with it. Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206132 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, Werner progeria, heterochromatin, senescence, nuclear lamina, satellite repeats About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss infectious disease activity around the nation. They cover:    The high prevalence of influenza A, avian influenza, measles, and COVID-19. Reliable resources for information on the spread of infectious diseases. Prevention measures and their impact on the spread of infectious diseases. The risks associated with multiple infectious diseases circulating simultaneously at high rates. 

On this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., speaks with senior associate dean of academic affairs for Mayo Clinic Alix School of Medicine, Joseph Maleszewski, M.D., on the future of basic sciences in medical education.Discussion includes:·       Challenges of basic science in medical education.·       Differing perspectives about basic science in medical education.·       Ideas of exploration for the future.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, for a conversation about innovation in testing for sexually transmitted infections (STI). Topics include: The advantages and challenges of new types of specimen collection and testing methods, including over-the-counter, at-home, and point-of-care options. Implications home testing has for clinicians and public health. Barriers to making more at-home collection and over-the-counter testing products for STI testing.The growing need for tests to detect resistance markers as antimicrobial resistance increases. 

Reference: Agnello et al. Monocyte distribution width (MDW) as a screening tool for early detecting sepsis: a systematic review and meta-analysis. Clinical Chemistry and Laboratory Medicine 2022; 60(5):786-792 Clin Chem Lab Med. 2022 Date: February 21, 2025 Guest Skeptic: Dr. Aaron Skolnik is an Assistant Professor of Emergency Medicine at the Mayo Clinic Alix School […] The post SGEM#468: Wide Open Monocytes – Using MDW to Diagnose Sepsis first appeared on The Skeptics Guide to Emergency Medicine.

In this episode of "Ask the Expert," Dr. Eoin Flanagan joined Dr. GG deFiebre of SRNA. Dr. Flanagan explained how immunosuppressive medications impact the immune system and the efficacy of vaccines [00:02:45]. He discussed the primary concerns and risks of vaccinating individuals on these therapies, including avoiding live vaccines and the need for additional booster doses [00:04:52]. Dr. Flanagan also talked about the recommended vaccines for those with conditions like NMOSD or MOGAD, and underlined the importance of getting vaccinated to prevent severe infections [00:09:40]. He addressed common misconceptions and emphasized the role of healthcare providers in educating and supporting their patients regarding vaccinations [00:15:32].Eoin Flanagan, MB, BCh is a Professor of Neurology and Consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic (Rochester, MN). He completed his medical school training at University College Dublin in Ireland in 2005. He did a medical residency in Ireland and then completed neurology residency, fellowships in neuroimmunology and a masters in clinical and translational science at Mayo Clinic (Rochester, MN). He works in the Autoimmune Neurology and Multiple Sclerosis Clinics and the Neuroimmunology Laboratory at the Mayo Clinic. His clinical expertise and research are focused on inflammatory myelopathies and their imaging patterns, myelin oligodendrocyte glycoprotein (MOG) antibody associated disorder, neuromyelitis optica spectrum disorders, autoimmune encephalitis, paraneoplastic neurologic disorders, and multiple sclerosis. He is principal investigator on an NIH RO1 grant studying MOG antibody associated disorder.00:00 Introduction 00:47 Understanding Immunosuppressants and Vaccines01:28 Primary Concerns with Vaccinating Immunosuppressed Patients02:30 Recommended Vaccines for Immunosuppressed Patients07:11 Timing and Effectiveness of Vaccinations08:21 Measuring Vaccine Response09:24 Addressing Missed Doses and Safety Considerations16:41 Public Health Implications and Patient Advocacy17:56 Advice for Vaccine-Hesitant Patients19:06 Healthcare Providers' Role in Vaccination20:03 Conclusion and Final Thoughts

Reprodução Humana Assistida (SciCast #631) Patronato do SciCast: 1. Patreon SciCast 2. Apoia.se/Scicast 3. Nos ajude via Pix também, chave: contato@scicast.com.br ou acesse o QRcode: Sua pequena contribuição ajuda o Portal Deviante a continuar divulgando Ciência! Contatos: contato@scicast.com.br https://twitter.com/scicastpodcast https://www.facebook.com/scicastpodcast https://instagram.com/scicastpodcast Fale conosco! E não esqueça de deixar o seu comentário na postagem desse episódio! Expediente: Produção Geral: Tarik Fernandes e André Trapani Equipe de Gravação: André Trapani, Marcelo de Matos, Gabriel Lima, Natalia Nakamura, Daniele Perondi, Letícia Aguiar Citação ABNT: Scicast #631: Reprodução Humana Assistida. Locução: André Trapani, Marcelo de Matos, Gabriel Lima, Natalia Nakamura, Daniele Perondi, Letícia Aguiar . [S.l.] Portal Deviante, 15/02/2025. Podcast. Disponível em: https://www.deviante.com.br/podcasts/scicast-631 Imagem de capa: Referências e Indicações Sugestões de literatura: Bioética e reprodução assistida. Infertilidade, produção e uso de embriões humanos. In: LOYOLA, M. A. (Org). Bioética, reprodução e gênero nas sociedades contemporâneas Campinas e Brasília: Abep e Letras-Livres, 2005ª. CORRÊA A, M. C. D. V. A tecnologia a serviço de um sonho. Um estudo da reprodução assistida no Brasil. Tese (doutorado em Saúde Coletiva) - Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro. Rio de Janeiro, 1997. MEIRA, A. R. Reprodução humana: a ética trinta anos depois. Revista Bioética, v. 16, n. 1, 2008. CORRÊA, Marilena C.D.V.; LOYOLA, Maria Andrea. Assisted reproductive technologies in Brazil: Options to improve access. Physis, [s. l.], v. 25, n. 3, p. 753–777, 2015. STEPTOE, P. C.; EDWARDS, R. G. Birth after the reimplantation of a human embryo. Archives of Pathology and Laboratory Medicine, [s. l.], v. 116, n. 4, p. 321, 1992. VAYENA, Effy; ROWE, Patrick J.; GRIFFIN, P. David. Current challenges in assisted reproduction. In: , 2002. Medical, Ethical and Social Aspects of Assisted Reproduction (2001: Geneva, Switzerland) Current practices and controversies in assisted reproduction : report of a WHO meeting / editors. [S. l.: s. n.], 2002. Sugestões de filmes: A estranha vida de Timothy Green Minhas mães e meu pai Gataca Sugestões de vídeos: Via Justiça - Biodireito, Bioética e Direitos Humanos - 1º Bloco Sugestões de links: Óvulo criado a partir de gametas masculinos https://jstories.media/article/mouse-ips See omnystudio.com/listener for privacy information.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, for a conversation about quality management. Specifically, they discuss: The benefit of investing in quality management for patients, staff, and the organization.How Mayo Clinic's Department of Laboratory Medicine and Pathology in Rochester evolved and grew its quality management program.The advantage of holding 5–10-minute huddles each day.How the lab leverages education on quality tools and Gemba Walks to empower all staff to invest in quality management.

On this episode of “Lab Medicine Rounds,” Just Kreuter, M.D., chats with Jennifer Boland Froemming, M.D., about creating the perfect rank list for training programs. Dr. Boland Froemming shares her insights and tips to help you make informed decisions.Discussion Includes:00:36 How rank lists work.03:45 What to consider when making a rank list.06:20 Recommendations for individuals applying to training programs.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss recent business trends in diagnostics and why it is important for pathologists to stay informed about these trends. Their conversation covers: What's driving a renewed interest in investing in diagnostics.Why the knowledge pathologists have is so valuable in the current landscape.How the evolving expectations of laboratory professionals will make it important to stay informed about business trends.

In this month's episode of Lab Medicine Rounds, Justin Kreuter, M.D., speaks with Monica Ibarra about the essential role of diversity, equity, and inclusion in healthcare and beyond. Timestamps:0:00 Introduction0:43 Why conversations about diversity are important3:56 Common challenges that arise during discussions6:11 Approaching conversations in different environments11:17 Leaders navigating challenging DEI conversations20:00 Diversity reflection questions to ask yourself

Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.Speaker 3: (00:32) Would you mind telling us a little bit about yourself and your background? Speaker 3: (01:58) Would you give us an overview of membranous nephropathy?  Speaker 3: (07:14) Could you tell us a little bit about this new assay? Speaker 3: (14:29) Could you give a little example of how a clinician might use this information to treat their patients differently than how they would've in the past?   

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss Dr. Morice's recent article in Becker's Hospital Review, “Nine Developments Predicted to Shape Laboratory Medicine and Diagnostics in 2025,” and go deeper into conversation about: The rapid evolution of artificial intelligence and large language models.Digital pathology.Proteomics, metabolomics, and mass spectrometry.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., speaks with Kristen Ruby, D.O., M.P.H., to discuss National Blood Donor Month and the impact blood donors make. Timestamps:00:00 Introduction00:47 Celebrating blood donors03:43 Types of blood donors11:16 Diversity of blood inventory17:17 Thank you19:22 Outro

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Erin Graf, Ph.D., co-director of Microbiology in the Department of Laboratory Medicine and Pathology at Mayo Clinic in Arizona, to discuss benefits of automation in the laboratory.   Topics of discussion include:Specific examples of how they are using automation in the laboratory. Strategies for ensuring a smooth implementation and a positive experience for staff. The potential of automation to support staff and continued patient care excellence amid projected labor shortages in the future. 

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss emerging concerns about H5N1 avian influenza. Specific topics of discussion include:Patterns of transmission and what they indicate about the potential of person-to-person transmission. Tools, tests, and processes that emerged in recent years that are making it easier to understand and track this virus. Remaining unknowns about the virus and how it could evolve. 

In this episode we discuss the recent National Society of Genetic Counselor's Practice Resource on Dystrophinopathies, which was recently published in JoGC, with two of the publications' authors. You can find the Journal of Genetic Counseling webpage via onlinelibrary.wiley.com or via the National Society of Genetic Counselors website.   Segment 1: “Genetic counseling for the dystrophinopathies- Practice resource of the National Society of Genetic Counselors”   Ann Martin, MS, CGC is a board certified genetic counselor with Parent Project Muscular Dystrophy (PPMD). Ann serves as the VP of Community Research and Genetic Services and manages a team of genetic counselors who coordinate all aspects of The Duchenne Registry and the Decode Duchenne genetic testing program. Since joining PPMD in 2011, Ann has been directly involved in all aspects of the Registry programs including collection and curation of the Registry data, clinical trial and research study recruitment, data exports, patient and family inquiries, genetic testing, and educational content on the PPMD websites. Ann represents The Duchenne Registry on TREAT-NMD's Global Data Oversight Committee, which is responsible for reviewing requests for data from the TREAT-NMD Global Registries, and serves as the DMD Subgroup Co-Lead. In addition, Ann has been a member of Sarepta Therapeutics' Advisory Board for Early Diagnosis of Duchenne since 2022. Ann is continually engaging and educating both the patient and professional community about the Registry and Duchenne and Becker research. Before joining PPMD, Ann worked as a clinical genetic counselor for 15 years at Carolinas Medical Center in Charlotte, NC, where she provided genetic counseling for pediatric and adult patients with a wide range of genetic disorders. Ann is a graduate of the University of Cincinnati Genetic Counseling Graduate Program. She is board-certified by the American Board of Genetic Counseling and is a member of the National Society of Genetic Counselors. Angela Pickart (she/her) is a licensed, certified genetic counselor practicing in the Genomics Laboratory at Mayo Clinic, performing variant interpretation, report writing and test development for neurogenetics assays. She received her Master of Science degree in Genetic Counseling at the University of Minnesota and has extensive clinical experience in pediatric, neurology, and oncology genetic counseling prior to transitioning to her laboratory role. She has been awarded the academic rank of Assistant Professor of Laboratory Medicine at the Mayo Clinic College of Medicine and Science where she serves as course co-director of the Center for Clinical and Translational Sciences Molecular Variant Evaluation Course. She is also the course co-director of the Laboratory Practicum for the Medical College of Wisconsin Master of Science Genetic Counseling Graduate Program and Adjunct Assistant Professor of the Medical College of Wisconsin School of Graduate Studies.   In this segment we discuss: - Origins and significance of the genetic counseling-specific practice resource for dystrophinopathies. - Changes in the treatment landscape due to FDA-approved therapeutics and ongoing clinical trials for dystrophinopathies. - Strategies for educating patients and families about the implications of genetic testing and diagnosis in dystrophinopathies. - Advocacy roles of genetic counselors in helping patients access the latest therapies and participate in clinical trials for DMD/BMD. - Importance of interdisciplinary collaboration in managing dystrophinopathies and the roles genetic counselors play within these teams. - Potential broader impact of the practice resource on the medical field and patient community.    Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors. Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.  For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.  Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.  DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Sydney Arlen.

In this episode of Lab Medicine Rounds, Justin Kreuter, M.D., speaks with education specialist Bob Jackson on the challenges and importance of being a lifelong learner. Timestamps:00:00 Introduction00:31 Importance of lifelong learning02:03 Challenges of lifelong learning06:07 Adapting to change10:58 Teaching and learning13:39 Embracing uncertainty17:00 Encouraging lifelong learning24:00 New Year's resolutions

Dr. Lena Ekström is a Hospital Chemist at Karolinska University Hospital and an Adjunct Professor of Pharmacology in the Department of Laboratory Medicine at the Karolinska Institute, where she specializes in Doping Research. In this interview, we discuss her career and some of the research she has conducted examining various factors that can influence anti-doping test results including interactions with other substances, genetics, hormone cycles, biological variability, and micro-dosing.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the progress of artificial intelligence (AI) and what's next in this space.Specific topics of discussion include:What's driving the rapid acceleration of AI advancements.Ethical concerns and opportunities.How expenses, payment models, and culture influence AI advancements.The need to rethink training and education amid the rise of AI solutions.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., speaks with medical students on the importance of understanding healthcare systems, their experiences from a global surgery hackathon, and how maintaining curiosity and continuous learning can enhance their medical practice.Timestamps:0:00 Introductions0:49 Importance of Understanding Healthcare Systems1:33 Fundamentals of Healthcare Systems3:03 Complexity of Healthcare Systems5:13 Selective vs Curriculum6:08 Systems and Inequalities7:18 Billing and Economics in Healthcare8:17 Balancing Medical Training and System Knowledge9:01 Curiosity and Continuous Learning10:02 Learning Opportunities13:02 Slowing Down in Critical Phases16:41 Revising Healthcare Systems18:02 Capturing Learning22:03 Maintaining Curiosity24:01 Advice for Developing Skills in Healthcare Systems

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the latest in infectious disease outbreaks.    Specific topics of discussion include:Recent trends in the spread of H5 bird flu and dengue fever. Why it's important to think globally when monitoring infectious diseases.Extra precautions to take during the holiday travel season to keep you and those around you healthy.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss how labs can enhance patient access to improve health equity.Specific topics of discussion include:Innovations creating new possibilities, such as mobile clinics, at-home tests, and artificial intelligence.The responsibility of laboratory professionals to help guide the use of these new tools and the importance of collaboration between health systems.What's needed to make solutions scalable and sustainable.Learn more in Dr. Morice's “Lab Manager” article. 

In this insightful episode, listeners will hear Dr. Alan Wu's innovative approach to raising public awareness about the vital role of laboratory medicine in healthcare. Through his advocacy, Dr. Wu aims to transform how lab medicine is perceived and appreciated by diverse audiences.Tune as as we unfold Dr. Alan Wu's Visionary Three-Step Plan to Advocate for the Laboratory Medicine profession!

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by genetic counselors Carrie Lahner, M.S., CGC, and April Studinski Jones, M.S., CGC, to discuss how family medical history can inform genetic testing strategies.   Specific topics of discussion include:The seven main types of genetic testing, and how clinicians know when and what genetic testing to order.Key family history details to collect to inform decisions about genetic testing. How genetic counselors collaborate with physicians and laboratorians to make testing decisions. Recent genetic testing advancements that are improving diagnostics. 

John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.Speaker 3: (00:32) Could you give us a brief overview about your background and yourself? Speaker 3: (02:16) Could you explain the role of the UGT1A1 gene and its significance in the pharmacogenomics of irinotecan?  Speaker 3: (05:34) What specific tests do we offer for UGT1A1 at Mayo Clinic Laboratories? Speaker 3: (08:01) Can you clarify the difference between targeted genotyping and full gene sequencing, and when each method is most appropriate? Speaker 3: (10:36)Could you elaborate on the specific clinical indications for testing in relation to irinotecan? Speaker 3: (13:27) How do UGT1A1 test results impact the dosing of irinotecan? What should clinicians consider when using those results?  Speaker 3: (14:02) Are there any other factors or related genes that should be considered alongside UGT1A1, particularly for cancer therapy?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss recent outbreaks in vaccine-preventable diseases.  Specific topics of discussion include:Recent increases in outbreaks of infectious diseases, such as pertussis, measles, and polio. The serious side effects of the diseases. What's fueling the resurgence of these diseases.Testing options for infectious diseases and resources for physicians.